Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765423 versus placebo in idiopathic pulmonary fibrosis
jRCT2031250432Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 765423 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Started Oct 2025; status: active, not recruiting.
02
Drugs
BI-765423
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2031250432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250432.